GENEVA--(BUSINESS WIRE)-- Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based ...
SEATTLE--(BUSINESS WIRE)--LumiThera, Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular damage and disease, today announced a new Category III CPT code ...
A pivotal clinical trial that cleared the way for US regulators to approve a new light therapy device as a treatment for macular degeneration has been criticized for several shortcomings, with a ...
SEATTLE--(BUSINESS WIRE)--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the topline results from the LIGHTSITE ...
A project involving Changzhou University, Shenzhen University and Xinxiang Medical University has used label-free imaging to monitor amyloid aggregation. The non-linear technique, described in ...
Alcon, the Geneva-headquartered eyecare company, has announced plans to acquire LumiThera, a US firm that is working on a multi-wavelength treatment for dry age-related macular degeneration (AMD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results